{"id":5543,"date":"2016-04-01T07:11:48","date_gmt":"2016-04-01T07:11:48","guid":{"rendered":"https:\/\/jurmed.ro\/medici\/?p=5543"},"modified":"2016-04-01T07:16:58","modified_gmt":"2016-04-01T07:16:58","slug":"5543-2","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/medici\/5543-2\/","title":{"rendered":"Cancerul de prostata – o noua speranta"},"content":{"rendered":"

\u00a0 \u00a0 \u00a0Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta \u201c O noua speranta pentru pacientii romani cu cancer de prostata\u201d.<\/p>\n

\u00a0 \u00a0 \u00a0Evenimentul a fost moderat de Dr. Marius Geanta iar ca invitati, Acad. Prof. Dr. Ioanel Sinescu, pre\u0219edinte al Asocia\u021biei Rom\u00e2ne de Urologie, Dr. Florin B\u0103canu, vicepre\u015fedinte Societatea Na\u0163ional\u0103 de Oncologie Medical\u0103 din Rom\u00e2nia, Dl. Cezar Irimia, pre\u015fedinte Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia precum si Dl. Mihai Stoiculescu, pacient diagnosticat cu cancer de prostat\u0103.<\/p>\n

\u00a0 \u00a0 \u00a0Cu aceasta ocazie, distinsii invitati au facut urmatoarele declaratii:<\/p>\n

\u00a0 \u00a0 \u00a0Acad. Prof. Dr. Ioanel Sinescu,<\/strong> pre\u0219edinte al Asocia\u021biei Rom\u00e2ne de Urologie: \u201cTo\u021bi b\u0103rba\u021bii care ar ajunge la v\u00e2rsta de 120 de ani ar suferi de cancer prostatic. Situ\u00e2ndu-se ca inciden\u021b\u0103 pe locul I, cancerul de prostat\u0103 \u00eei \u00eenso\u021be\u0219te, pe mul\u021bi dintre b\u0103rba\u021bi, o lung\u0103 perioad\u0103 de timp. Cancerul de prostat\u0103 nu poate fi prevenit, dar depistarea afec\u021biunii \u00een stadii incipiente ofer\u0103 \u0219anse reale de vindecare. Orice b\u0103rbat trecut de v\u00e2rsta de 50 de ani trebuie s\u0103 fie evaluat anual, pentru a i se confirma s\u0103n\u0103tatea prostatei. Evaluarea const\u0103 \u00een determinarea nivelului seric al antigenului specific prostatic (PSA), ecografia aparatului urinar \u0219i tu\u0219eul rectal. \u00cen stadii precoce, cancerul prostatic este asimptomatic. Apari\u021bia unor semne clinice de tipul urin\u0103rii frecvente, dificile, senza\u021bia de evacuare vezical\u0103 incomplet\u0103 etc. impun evaluarea urologic\u0103 chiar \u00eenainte de v\u00e2rsta de 50 de ani. Depistarea precoce a cancerului prostatic ofer\u0103 \u0219ansa controlului bolii pe termen lung sau chiar a vindec\u0103rii. Spre deosebire de alte forme de neoplazie, cancerul de prostat\u0103 permite o supravie\u021buire mai lung\u0103, cu o calitate a vie\u021bii mai bun\u0103, \u00een condi\u021biile diagnosticului precoce \u0219i a tratamentului adaptat stadiului evolutiv al afec\u021biunii\u201d.<\/p>\n

\"cancerul<\/p>\n

\u00a0 \u00a0 \u00a0Dr. Florin B\u0103canu<\/strong>, vicepre\u015fedinte Societatea Na\u0163ional\u0103 de Oncologie Medical\u0103 din Rom\u00e2nia: \u201cMajoritatea pacien\u0163ilor nou diagnostica\u0163i cu cancer de prostat\u0103 r\u0103spund ini\u0163ial bine la tratamentul chirurgical sau medical. Rat\u0103 de supravie\u0163uire a cancerului de prostat\u0103 este mare. Studii din SUA raport\u00e2nd o rat\u0103 de supravie\u0163uire la 5 ani de 100% c\u00e2nd boala se manifest\u0103 la nivel localizat sau regional. Cu toate acestea, la peste 5 ani de la diagnostic, vasta majoritate a pacien\u0163ilor dezvolt\u0103 o boal\u0103 progresiv\u0103, rezistent\u0103 la tratamentele hormonale. \u00cen timp, evolu\u0163ia bolii devine mai rapid\u0103, iar 40% dintre pacien\u0163ii diagnostica\u0163i cu boala localizat\u0103 progreseaz\u0103 la stadiul metastatic (95% la nivelul sistemului osos). \u00cen general, la doi ani dup\u0103 apari\u0163ia metastazelor, pacien\u0163ii dezvolt\u0103 rezisten\u0163\u0103 la tratamentele hormonale. P\u00e2n\u0103 de cur\u00e2nd, op\u0163iunile de tratament pentru cancerul de prostat\u0103 metastatic rezistent la tratamentele hormonale erau limitate (chimioterapie) \u015fi erau asociate cu efecte adverse ce aveau un impact negativ asupra calit\u0103\u0163ii vie\u0163ii. Dup\u0103 chimioterapie, singura op\u0163iune era \u00eengrijirea paleativ\u0103. Aprobarea de c\u0103tre EMA, \u00een 2011, a primului agent non-chimioterapeutic pentru aceast\u0103 categorie de pacien\u0163i (abiraterona) a \u00eensemnat schimbarea paradigmei de tratament \u00een cancerul de prostat\u0103 metastatic rezistent la tratamentele hormonale. Tratamentul cu abiraterona este disponibil acum \u015fi pacien\u0163ilor rom\u00e2ni, rezolv\u00e2nd astfel una dintre situa\u0163iile critice din oncologie, \u00een care nu aveam alte solu\u0163ii terapeutice etiologice la \u00eendem\u00e2n\u0103\u201d.<\/p>\n

\u00a0 \u00a0 \u00a0Dl. Cezar Irimia<\/strong>, pre\u015fedinte Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia: \u201cFa\u0163\u0103 de alte forme de cancer, \u00een privin\u0163a cancerului de prostat\u0103 st\u0103m ceva mai bine din perspectiva accesului la noile tratamente inovatoare. Anul trecut, a fost aprobat pentru compensare \u015fi unul dintre noile medicamente care se adreseaz\u0103 pacien\u0163ilor cu cancer de prostat\u0103 metastatic \u015fi care nu mai r\u0103spundeau la celelalte tratamente medicamentoase disponibile. S-a acoperit astfel o nevoie terapeutic\u0103 major\u0103, \u00een lipsa acestui tratament pacien\u0163ii find practic condamna\u0163i la moarte. Sper\u0103m c\u0103 pacien\u0163ii cu cancer de prostat\u0103 s\u0103 aib\u0103 acces gratuit \u015fi complet \u015fi \u00een anii urm\u0103tori la aceste medicamente de ultima genera\u0163ie\u201d<\/p>\n

\u00a0 \u00a0 \u00a0Dr. Marius Geant\u0103<\/strong>, co-fondator \u015fi pre\u015fedinte Centrul pentru Inova\u0163ie \u00een Medicin\u0103: \u201c23 de luni trec, \u00een medie, din momentul \u00een care apar primele semne de afectare a aparatului urinar \u015fi momentul \u00een care b\u0103rbatul se decide s\u0103 rup\u0103 t\u0103cerea \u015fi s\u0103 se adreseze medicului pentru investiga\u0163ii suplimentare. De cele mai multe ori, nu o face singur, ci la \u00eendemnul partenerei. Cei aproape doi ani de suferin\u0163\u0103 \u00een lini\u015fte pot face diferen\u0163a dintre via\u0163\u0103 \u015fi moarte. Cu c\u00e2t diagnosticul de cancer de prostat\u0103 se pune mai repede, cu at\u00e2t \u015fansa de supravie\u0163uire pe termen lung cre\u015fte considerabil. Medicina modern\u0103, genomic\u0103, ne pune la dispozi\u0163ie instrumente sofisticate de diagnostic, care pot indica riscul de boal\u0103 \u00een situa\u0163ia \u00een care, \u00een familie, au mai existat cazuri de cancer de prostat\u0103 sau care pot s\u0103 indice dac\u0103 o form\u0103 de cancer de prostat\u0103 este agresiv\u0103 \u015fi necesit\u0103 interven\u0163ie chirurgical\u0103 sau este lent evolutiv\u0103 \u015fi trebuie doar supravegheat\u0103 clinic cu aten\u0163ie. Al\u0103turi de clasica analiz\u0103 PSA, \u00een practica medical\u0103 curent\u0103 trebuie s\u0103-\u015fi g\u0103seasc\u0103 locul \u015fi aceste teste genetice din ce \u00een ce mai performante, \u00eempreun\u0103 cu mijloacele inovatoare de tratament chirurgical, radioterapeutic \u015fi medicamentos\u201d.<\/p>\n

\u00a0 \u00a0 \u00a0Dl. Mihai Stoiculescu<\/strong>, pacient diagnosticat cu cancer de prostat\u0103: \u201eLa 59 de ani, \u00eempins de la spate de so\u021bia mea, am mers pentru prima dat\u0103 la un consult la medicul urolog. Nu aveam nici o sup\u0103rare, nici un simptom, trebuia s\u0103 fie doar un control de rutin\u0103. Doar c\u0103 \u00een urma acelui consult, mi s-a spus c\u0103 am probleme cu prostata. Primul tratament recomandat de dr. Sinescu de la Spitalul Fundeni, a fost de radioterapie. Am urmat 40 de \u0219edin\u021be zilnice, \u00een urma c\u0103rora valoarea testului PSA a sc\u0103zut de la 16, la 1,31. Lucrurile au \u00eenceput s\u0103 evolueze destul de rapid dup\u0103 trecerea acestor ani, astfel c\u0103 dup\u0103 un nou control, de aceast\u0103 dat\u0103 la dr. B\u0103canu, mi-a fost recomandat tratamentul cu hormonoterapie. C\u00e2\u021biva ani, p\u00e2n\u0103 la sf\u00e2r\u0219itul anului 2014, medicamentele au \u021binut \u00een fr\u00e2u valorile PSA, dar cur\u00e2nd au \u00eenceput s\u0103 creasc\u0103 din ce \u00een ce mai mult, de la 130-160, la valoarea 603 \u00een luna februarie a acestui an. Atunci, am \u00eenceput tratamentul cu abirateron, iar dup\u0103 doar o lun\u0103, valoarea PSA a sc\u0103zut la 188.<\/p>\n

\u00a0 \u00a0 Am urmat toate terapiile cunoscute pentru aceast\u0103 boal\u0103: radioterapie, hormonoterapie, chimioterapie \u0219i aceasta a fost tot ce puteam face ca pacient diagonosticat cu cancer de prostat\u0103. Pe mine, acest nou tratament m\u0103 face s\u0103 fiu optimist, s\u0103 privesc \u00eenainte, m\u0103 face s\u0103 cred c\u0103 voi apuca s\u0103 \u00eemplinesc \u0219i 80 de ani sau poate chiar mai mult, s\u0103-mi v\u0103d str\u0103nepo\u021bii!<\/p>\n

\u00a0 \u00a0 \u00a0\u00cemi p\u0103strez optimismul, nu m\u0103 g\u00e2ndesc c\u0103 sunt bolnav \u0219i a\u0219 vrea s\u0103 le transmit tuturor pacien\u021bilor cu aceea\u0219i boal\u0103, s\u0103 nu intre \u00een panic\u0103! Medicina are r\u0103spuns pentru toate!\u201d<\/p>\n

\u00a0 \u00a0 \u00a0 Ca o sinteza a celor discutate putem distinge urmatoarele:<\/strong><\/p>\n

\u2022 O nou\u0103 speran\u0163\u0103 pentru pacien\u0163ii rom\u00e2ni cu cancer de prostat\u0103 \u00een faz\u0103 terminal\u0103: ei beneficiaz\u0103 acum de un nou tratament. Abiraterona este inclus\u0103 \u00een programul na\u021bional. Pacien\u021bii rom\u00e2ni pot avea acces la acest tratament \u00een mod gratuit, pe baza recomand\u0103rii de la doctorul oncolog.<\/p>\n

\u2022 Un diagnostic precoce poate salva via\u021ba fiec\u0103rui b\u0103rbat. Mul\u021bi dintre rom\u00e2ni ignor\u0103 primul semn al prostatei (urinatul frecvent pe timpul nop\u021bii) \u0219i nu se duc la medic dec\u00e2t \u00een urma insisten\u021belor partenerei de via\u021b\u0103. \u00cen cazul unui istoric \u00een familie, primul consult medical trebuie f\u0103cut la 40 de ani, iar f\u0103r\u0103 istoric \u00een familie, la 50 de ani.<\/p>\n

\u2022 Cele mai folosite modalit\u0103\u021bi de tratament \u00een cancerul de prostat\u0103 erau p\u00e2n\u0103 acum radioterapia, tratamentul cu hormoni (hormonoterapia) \u0219i chimioterapia, fiecare dintre ele asociate cu efecte adverse ce au impact negativ asupra calit\u0103\u021bii vie\u021bii pacien\u021bilor. Noul tratament (abiraterona) este neinvaziv, prelunge\u0219te \u0219i \u00eembun\u0103t\u0103\u021be\u0219te via\u021ba bolnavului.<\/p>\n

Despre cancerul de prostat\u0103<\/strong><\/p>\n

Cifre pentru Rom\u00e2nia
\n\u2022 Este a 5-a cauz\u0103 de deces prin cancer \u00een Rom\u00e2nia (pe primul loc se situeaz\u0103 cancerul de pl\u0103m\u00e2ni). *
\n\u2022 Inciden\u021ba apari\u021biei acestui tip de cancer \u00een r\u00e2ndul popula\u021biei masculine este de 10,5%, conform unui studiu din 2012. *
\n\u2022 4.532 de cazuri noi de cancer de prostat\u0103 sunt estimate anual.
\n\u2022 2.018 b\u0103rba\u021bi mor anual din cauza cancerului de prostat\u0103. *
\nCifre mondiale
\n\u2022 1,1 milioane de cazuri au fost diagnosticate \u00een 2012. ****
\n\u2022 400.000 de cazuri noi sunt depistate \u00een Europa. ****
\n\u2022 Este a 2-a cea mai frecvent\u0103 diagnosticat\u0103 form\u0103 de cancer la b\u0103rba\u021bi \u2013 15% din toate cancerele.****
\n\u2022 307.000 de decese \u00eenregistrate anual. *****<\/p>\n

Ce trebuie s\u0103 \u0219tii despre cancerul de prostat\u0103<\/strong><\/p>\n

\u2022 Cancerul de prostat\u0103 este o afec\u021biune malign\u0103 a glandei prostatice, un organ de m\u0103rimea unei castane, situat\u0103 sub vezica urinar\u0103 a b\u0103rbatului. **
\n\u2022 Cele mai des \u00eent\u00e2lnite simptome ale cancerului de prostat\u0103 sunt: urinarea frecvent\u0103, dificult\u0103\u021bi la \u00eenceputul urin\u0103rii, trezitul \u00een timpul nop\u021bii pentru a urina de mai multe ori, senza\u021bia c\u0103 trebuie s\u0103 urinezi imediat. ***
\n\u2022 Un test de s\u00e2nge (PSA \u2013 Antigenul specific prostatic) poate detecta cancerul de prostat\u0103 \u00een stadiu precoce, deci vindecabil. **
\n\u2022 Cele mai frecvente tratamente \u00eempotriva cancerului de prostat\u0103 sunt tratamentele cu hormoni antitumorali \u0219i medicamentele citostatice. **
\n\u2022 Principalii factori de risc: v\u00e2rsta (peste 50 de ani, riscurile cresc exponen\u021bial \u00een fiecare an), etnia (b\u0103rba\u021bii albi \u0219i asiatici au un risc mai mic de a dezvolta boala), ereditatea, nivelul crescut de testosteron). Al\u021bi factori sunt: dieta dezechilibrat\u0103 (conform unor studii, consumul excesiv de carne ro\u0219ie cre\u0219te u\u0219or riscul de cancer de prostat\u0103), stilul de via\u021b\u0103 (fumatul). ***
\n\u2022 Cancerul de prostat\u0103 apare rar sub v\u00e2rsta de 40 de ani \u015fi este cu prec\u0103dere o boal\u0103 a b\u0103rbatului dup\u0103 65 de ani. **
\n\u2022 B\u0103rba\u021bii cu indice de mas\u0103 corporal\u0103 mai mare de 32.5% au un risc de apari\u021bie a cancerului de prostat\u0103 cu o treime mai mare dec\u00e2t ceilal\u021bi. ***<\/p>\n

Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta \u201c O noua speranta pentru pacientii romani cu cancer de prostata\u201d.
\n* International Agency for Reasearch on Cancer (http:\/\/eco.iarc.fr\/eucan\/Country.aspx?ISOCountryCd=642)
\n**romaniancancerleague.org ***www.esmo.org
\n**** European Commission. CORDIS Express: Prevention, diagnosis and treatment of prostate cancer (http:\/\/cordis. europa.eu\/news\/rcn\/122705_en.html)
\n*****globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a0 \u00a0 \u00a0Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta \u201c O noua speranta pentru pacientii romani cu […]<\/p>\n","protected":false},"author":1,"featured_media":5544,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[476,509,510,511,512],"class_list":["post-5543","post","type-post","status-publish","format-standard","has-post-thumbnail","category-stiri-noutati","tag-cancer","tag-cancerul-de-prostata","tag-florin-bacanu","tag-ioanel-sinescu","tag-psa"],"yoast_head":"\nCancerul de prostata - o noua speranta - Jurmed - Medici<\/title>\n<meta name=\"description\" content=\"Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta a carei tematica a vizat cancerul de prostata.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/medici\/5543-2\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancerul de prostata - o noua speranta - Jurmed - Medici\" \/>\n<meta property=\"og:description\" content=\"Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta a carei tematica a vizat cancerul de prostata.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/medici\/5543-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Medici\" \/>\n<meta property=\"article:published_time\" content=\"2016-04-01T07:11:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-04-01T07:16:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"344\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Gabriel\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gabriel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/\"},\"author\":{\"name\":\"Gabriel\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa\"},\"headline\":\"Cancerul de prostata – o noua speranta\",\"datePublished\":\"2016-04-01T07:11:48+00:00\",\"dateModified\":\"2016-04-01T07:16:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/\"},\"wordCount\":1761,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg\",\"keywords\":[\"Cancer\",\"cancerul de prostata\",\"Florin B\u0103canu\",\"Ioanel Sinescu\",\"PSA\"],\"articleSection\":[\"Stiri \/ Noutati\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/medici\/5543-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/\",\"url\":\"https:\/\/jurmed.ro\/medici\/5543-2\/\",\"name\":\"Cancerul de prostata - o noua speranta - Jurmed - Medici\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg\",\"datePublished\":\"2016-04-01T07:11:48+00:00\",\"dateModified\":\"2016-04-01T07:16:58+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa\"},\"description\":\"Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta a carei tematica a vizat cancerul de prostata.\",\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/medici\/5543-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg\",\"contentUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg\",\"width\":600,\"height\":344},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/medici\/5543-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/medici\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cancerul de prostata – o noua speranta\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\",\"url\":\"https:\/\/jurmed.ro\/medici\/\",\"name\":\"Jurmed - Medici\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/medici\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa\",\"name\":\"Gabriel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g\",\"caption\":\"Gabriel\"},\"url\":\"https:\/\/jurmed.ro\/medici\/author\/gabrielb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cancerul de prostata - o noua speranta - Jurmed - Medici","description":"Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta a carei tematica a vizat cancerul de prostata.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/medici\/5543-2\/","og_locale":"ro_RO","og_type":"article","og_title":"Cancerul de prostata - o noua speranta - Jurmed - Medici","og_description":"Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta a carei tematica a vizat cancerul de prostata.","og_url":"https:\/\/jurmed.ro\/medici\/5543-2\/","og_site_name":"Jurmed - Medici","article_published_time":"2016-04-01T07:11:48+00:00","article_modified_time":"2016-04-01T07:16:58+00:00","og_image":[{"width":600,"height":344,"url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg","type":"image\/jpeg"}],"author":"Gabriel","twitter_misc":{"Scris de":"Gabriel","Timp estimat pentru citire":"9 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/medici\/5543-2\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/5543-2\/"},"author":{"name":"Gabriel","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa"},"headline":"Cancerul de prostata – o noua speranta","datePublished":"2016-04-01T07:11:48+00:00","dateModified":"2016-04-01T07:16:58+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/5543-2\/"},"wordCount":1761,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg","keywords":["Cancer","cancerul de prostata","Florin B\u0103canu","Ioanel Sinescu","PSA"],"articleSection":["Stiri \/ Noutati"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/medici\/5543-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/medici\/5543-2\/","url":"https:\/\/jurmed.ro\/medici\/5543-2\/","name":"Cancerul de prostata - o noua speranta - Jurmed - Medici","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg","datePublished":"2016-04-01T07:11:48+00:00","dateModified":"2016-04-01T07:16:58+00:00","author":{"@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa"},"description":"Luni, 29 martie 2016, Federa\u0163ia Asocia\u0163iilor Bolnavilor de Cancer din Rom\u00e2nia (FABC) cu sprijinul companiei farmaceutice Janssen, a organizat conferinta a carei tematica a vizat cancerul de prostata.","breadcrumb":{"@id":"https:\/\/jurmed.ro\/medici\/5543-2\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/medici\/5543-2\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/5543-2\/#primaryimage","url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg","contentUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2016\/04\/cancerul-de-prostata-600x300.jpg","width":600,"height":344},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/medici\/5543-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/medici\/"},{"@type":"ListItem","position":2,"name":"Cancerul de prostata – o noua speranta"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/medici\/#website","url":"https:\/\/jurmed.ro\/medici\/","name":"Jurmed - Medici","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/medici\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa","name":"Gabriel","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g","caption":"Gabriel"},"url":"https:\/\/jurmed.ro\/medici\/author\/gabrielb\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/5543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/comments?post=5543"}],"version-history":[{"count":4,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/5543\/revisions"}],"predecessor-version":[{"id":5548,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/5543\/revisions\/5548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media\/5544"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media?parent=5543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/categories?post=5543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/tags?post=5543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}